Q-omics provides the consensus-scored RNF212B profile across patient tissues and cancer cell-line models. RNF212B expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RNF212B is differentially expressed in 8, with the highest sampling consensus in KIRP. Additionally, RNF212B RNA expression shows 18,180 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KIRP, and UVM as cancer lineages where RNF212B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF212B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF212B survival associations across molecular data types. RNF212B RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF212B RNA expression–survival associations across cancer types. High RNF212B expression shows unfavorable associations in ACC, CHOL and UCEC, but favorable associations in KIRC, MESO and LAML. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .009). Together, the overview and detailed table identify ACC as the clearest survival context for RNF212B RNA expression.
This table summarizes RNF212B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RNF212B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF212B shows lower tumor expression in KIRP, KIRC, THCA and KICH and higher tumor expression in HNSC and BRCA. The KIRP box plot shows higher RNF212B RNA expression in normal versus tumor tissue (log2 FC = −2.320, t-test p < 0.001).
This table shows molecular features associated with RNF212B in patient tissues and cancer cell lines. In patient samples, RNF212B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF212B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BREAST.
